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Summary 
Objective: Establishing a core set of outcomes to be evaluated and reported in intervention 
trials aims to improve the usefulness of health research. There is no established core 
outcome set (COS) for childhood epilepsies. The aim of this study was to select a COS to be 
used in evaluative research of interventions for children with rolandic epilepsy (RE). 
Methods: We followed guidance from the COMET (Core Outcome Measures in Effectiveness 
Trials) Initiative. First, we identified outcomes that had been measured in research through 
a systematic review. Second, young people with RE, parents and professionals were invited 
to take part in a Delphi survey in which participants rated the importance of candidate 
outcomes. Last, a face-to-face meeting was convened to seek consensus on which outcomes 
were critical to include and to ratify the final COS.  
Results: From 37 eligible papers in the review we identified and included 48 candidate 
outcomes in the survey. We sent invitations to 165 people registered to take part in the 
survey; of these 102 (62%) completed Round 1, and 80 (78%) completed Round 2 (three 
young people, 16 parents, 61 professionals). In Round 2 we included four additional 
outcomes suggested by participants in Round 1. The consensus meeting included two young 
people, four parents and nine professionals who were eligible to vote and ratified the COS 
as 39 outcomes across 10 domains.  
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Significance: Our methodology was a proportionate and pragmatic approach towards 
producing a COS for evaluating research of interventions aiming to improve the health of 
children with RE. 
  
Key words: Epilepsy; children; young people; paediatric; core outcome set. 
Key point box 
- There was no established core outcome set for childhood epilepsy. 
- Consensus based methods were used to rate the importance of different outcomes 
in rolandic epilepsy (RE). This included two-rounds of a Delphi survey and a face-to-
face meeting that included young people with RE, parents and various professionals. 
- We identified 39 outcomes across 10 domains that contributed towards a core 
outcome set for use in epilepsy research. 
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Introduction 
Epilepsy is a common neurological disorder that can be defined by a persisting tendency for 
epileptic seizures. Epilepsy encompasses many different conditions including around 30 
different epilepsy syndromes and affects people of all ages, including children 1. Seizure 
reduction, freedom from seizures, or a significant reduction in duration and intensity of 
seizures are typical primary outcomes in trials evaluating interventions for epilepsy.  
However, it is important to consider the adverse effects of antiepileptic medication as well 
as non-seizure outcomes, particularly in developing children. 
 
The social and psychological consequences of seizures and children’s perspectives are 
becoming more valued, and health-related quality of life (HRQoL) is an increasing focus for 
research 2. It is important to consider that epilepsy-specific quality of life is not determined 
by seizures alone but can also be influenced by the child’s learning, mental health and social 
support 3,4. To overcome these issues, it is crucial to decide a core set of outcomes that are 
of greater importance to children and their families. 
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The variety of outcomes assessed in research and the different ways outcomes are 
measured can reduce the ability to combine and compare studies 5. Recognising a core set 
of outcomes to be measured and reported in all trials of interventions for specific conditions 
aims to advance the usefulness of research and avoid waste 6–8. A core outcome set (COS) 
that recommends the same suite of outcomes measured in the same way reduces both 
heterogeneity between studies and outcome reporting bias. It can also increase the 
potential for carrying out meta-analysis for important outcomes. The development of a COS 
should include the views of patients, carers and health professionals 7. A COS may also be 
useful for other types of research, clinical audit, and structuring routinely collected health 
services clinical data. A COS specifies which aspects of health are to be assessed and how to 
measure them. 
 
Currently there is no COS for evaluative research of interventions in children with epilepsy. 
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative database recently 
added a study focused on West Syndrome 9 and a study conducted in Sri Lanka on the 
development of outcome criteria to measure effectiveness of anti-epileptic medication 10. 
The National Institute for Health Care and Excellence (NICE) guidelines recommend seizure 
freedom as a primary outcome alongside seizure reduction, quality of life and cognitive 
functioning as secondary outcomes 11. Cochrane reviewers advise focusing on longer-term 
outcomes such as psychosocial and health economic outcomes 12. Scottish guidance 
recommends including aspects of academic attainment and mental health outcomes 13 and 
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the International League Against Epilepsy (ILAE) has published guidance on outcome 
measurement for clinical trials 14,15. Children are included in the Common Data Elements 
recommended for epilepsy research by the National Institute of Neurological Disorders and 
Stroke (NINDS) 16. The NINDS recommend a comprehensive list of items across various 
domains but children and parents were not consulted in the process 16. 
 
The aim of this study was to develop a COS relevant to evaluative research of interventions 
for children with rolandic epilepsy (RE), as an exemplar of common childhood epilepsy 
syndromes. RE is also known as ‘childhood epilepsy with centrotemporal spikes’ in the 
revised ILAE Classification 1. RE is the most common childhood epilepsy affecting 17-25% of 
children with epilepsy in the 5-14 year age range 17–19. The syndrome is associated with 
specific neuropsychological impairments such as in speech and language, literacy, attention 
as well as motor coordination deficits but is not associated with autism spectrum disorder 
or intellectual disability 20–22. Our study focused on children of school age (5 to 16 years old) 
with RE and our protocol is published 23. Specifically, our objectives were to review 
published research to identify outcomes reported in research and to seek consensus on 
which outcomes were perceived to be most important to measure in research. The work 
was conducted in partnership with families, health professionals and epilepsy charities in 
the UK.  
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Our work is motivated by the necessity to change the agenda from a seizure-centred 
medical model towards broader child and family priorities and to focus scarce resources on 
the most important outcomes 24. Our primary aim was to propose a COS for evaluative 
trials, but the findings may also inform decisions on outcomes measured in audits and/or 
routinely collected services data. The scope of this study included outcomes of any medical 
or social intervention where the aim was to improve the health of children with epilepsy 
and was not limited to medication. This study is part of a programme of work aiming to 
improve broad HRQoL for children with epilepsy. The COS will inform decisions about 
outcomes to be measured in a future clinical trial evaluating interventions for RE scheduled 
to begin recruitment in 2019.  
 
Methods 
Ethics and registration 
The study was conducted in line with COMET methodological recommendations, 25 with a 
published protocol 23 and was registered on the COMET database (www.comet-
initiative.org/studies/details/1030). Our study was approved by the NHS Health Research 
Authority (North East – Newcastle & North Tyneside 1 Research Ethics Committee: 
reference 18/NE/0014). Participants registered for the Delphi survey through our website 
(www.castlestudy.org.uk). Taking part in the Delphi was regarded as implicit consent. Young 
people took part in the Delphi if their parents agreed and provided them with the online 
Delphi link. Written consent was gathered at the face-to-face consensus meeting for 
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parents, young people and professionals. The study is reported in line with the Core 
Outcome Set - Standards for Reporting (COS-STAR) guidance 26, the GRIPP2 short form for 
Patient and Public Involvement (PPI) 27 and the review is reported with reference to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 28. 
 
To develop the COS we undertook three steps: (1) identifying candidate outcomes; (2) rating 
the importance of candidate outcomes in a 2-round Delphi survey; and (3) a face-to-face 
consensus meeting to ratify results of the Delphi survey and agree core outcomes. We 
convened an advisory Panel (AP) of young people with epilepsy and their carers alongside to 
consult on various decisions throughout each step.  
 
Step 1. Identifying candidate outcomes 
We identified candidate outcomes via structured, systematic review methods described in 
our protocol 23. Briefly, we looked for 1) primary evaluations and systematic reviews of 
interventions for RE; 2) qualitative or mixed methods studies about experiences and 
preferences for outcomes; and 3) epilepsy-specific and generic patient-reported outcome 
measures used with children with epilepsy. We searched for systematic reviews using terms 
for rolandic or childhood epilepsy in the Cochrane Database of Systematic Reviews, 
MEDLINE (via OvidSp), Embase (via OvidSp), PsycINFO (via OvidSp) and CINAHL (via 
EBSCOhost). We searched for controlled trials via the CENTRAL database and checked 
previously found systematic reviews for additional relevant trials. We also searched the 
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World Health Organisation International Clinical Trials Registry Platform for ongoing trials. 
Finally, we searched for qualitative or mixed methods research on MEDLINE, CINAHL and 
PsycINFO using terms for epilepsy combined with terms for qualitative research, experience 
and health related quality of life terms. The electronic search was carried out in October 
2017 by MR (Supplementary materials S1). HC reviewed and screened the abstracts and 
selected references. Decisions on eligibility where there was uncertainty were made in 
consultation with two other reviewers (CM and DP). As outlined in our protocol23 two 
people did not screen the references independently as the additional resources were not 
justified by the risk of missing outcome domains as we expected considerable duplication.  
HC coded outcomes extracted from the papers in consultation with CM using the COMET 
taxonomy;29 any doubts about coding were resolved in consultation with the wider team. 
HC extracted and entered information from the papers into spreadsheets including; 
population, outcomes, measurement instruments and any other salient information and 
then summarised in the table (Supplementary materials S2). We did not assess risk of bias 
for included studies as this was not relevant to the aim of this study. 
 
Step 2. Rating the importance of outcome domains in a 2-round Delphi survey  
The outcome domains identified in step 1 were taken forward for importance rating in a 
Delphi survey. We conducted the online Delphi survey over two rounds (R1 and R2) using 
DelphiManager software 30. Our protocol proposed three rounds but we shortened this to 
two rounds to reduce potential attrition and mitigate time constraints. We recruited 
participants from three key stakeholder groups: young people with RE aged 7-16 years, 
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parents of children with RE and professionals working with this group of children 
(paediatricians, paediatric neurologists, epilepsy specialist nurses etc). We recruited 
participants through various platforms including epilepsy charities, professional societies, 
and regional networks via OPEN UK (Organisation of Paediatric Epilepsy Networks).  We 
posted advertisements on social media platforms (e.g. Facebook and Twitter). Four NHS 
hospitals were set up as Participant Identification Centres (PIC) to enable clinicians to recruit 
patients, parents and colleagues. We directed interested participants to the study website 
where they could register using an online form.  
 
Participants were asked to rate the importance of each outcome in the Delphi survey using 
a scale from 1-9 in which options 1-3 were labelled ‘less important’, options 4-6 were 
‘important but not critical’, and options 7-9 indicated ‘critical for inclusion’ in the COS. 
Participants were able to suggest additional outcomes in R1, which were considered by the 
core team members for inclusion in R2 (Supplementary materials 4). We considered if the 
suggested outcomes were in fact different from the concepts already covered in the existing 
Delphi and whether they had been suggested by more than one person. In R2, participants 
were shown the distribution of other stakeholders’ scores from R1 in histograms as well as 
their own R1 score. They were asked to use this information to reflect on their score and 
rate the outcome again. Participants were able to give reasons for changing their score and 
leave free text comments.  
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We sent the Delphi survey link to people who registered interest online with a valid email 
address. R1 and R2 were open for two weeks each with a one-week interval in between. 
After R2 closed we downloaded the participant data and converted them into the 
percentage of stakeholders scoring from 1-9 across all outcomes. Our pre-defined 
consensus criteria were: (i) most important ‘core’ outcomes agreed by most stakeholders 
(>70% in each stakeholder group rated 7-9), (ii) less important outcomes (>70% in each 
stakeholder group rated 1-3) and (iii) those where there was partial or no agreement.  
 
Step 3: Consensus meeting 
Results from R2 of the online Delphi (Table 3) were shown at a face-to-face half-day 
meeting in London. We sent invitations to participants who had completed both R1 and R2 
of the Delphi. We encouraged parents to bring their children to the meeting if their child 
had also taken part in the Delphi. Travel costs were reimbursed on behalf of participants as 
well as a payment given to non-salaried individuals. All three stakeholder groups were 
represented in the meeting (Supplementary material S5). A member of the research team 
(CM) chaired the meeting and ground rules were agreed to ensure that all participants felt 
comfortable about speaking out in the group. 
Outcomes that had met the a priori criteria of ‘consensus in’ from the Delphi were initially 
displayed - all participants agreed that no further discussion was needed about their 
inclusion in the COS. All the remaining ‘no consensus’ outcomes were displayed and 
discussed in the meeting.  We gave participants red and green cards to vote with. Holding 
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up a red card meant that the outcome was not important enough to include in the COS. 
Holding up a green card meant that the participant thought it critical that the outcome be 
included. The chair ensured that contrasting views about voting were discussed and that 
equal opportunity was given to participants to discuss their voting decisions. Outcomes 
meeting the criteria for ‘consensus in’ during the meeting were incorporated into the COS. 
The final COS was presented and ratified to the group via email after the meeting so that 
people could have further time to think on their decisions and confirm.  
 
Patient and Public Involvement: 
Two parents of children with epilepsy were co-applicants when we sought funding for the 
programme of research within this nested study and are coinvestigators. A Family 
Engagement Officer (FEO) convened an AP in the south of England to involve young people 
and parents as meaningful partners in the development and implementation of our 
research. The FEOs recruited young people with epilepsy and their parents through various 
UK charities (Young Epilepsy, Epilepsy Action, Epilepsy Research UK), clinical networks 
(including consultant clinics and epilepsy specialist nurses), word-of-mouth, online parent 
forums and social media groups. We consulted AP members through face-to-face meetings 
and also remotely using email and phone. The AP members were involved in reviewing the 
CHOICE documents sent to the ethics committee and the Delphi survey. Members of the AP 
were asked to consider ease of the instructions and use of the survey. 
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AP members gave insight as to the ease of the Delphi survey and the relevance of outcomes. 
Modifications were made to the Delphi survey based on AP feedback and some wording for 
Delphi instructions were changed. Two parent lay co-applicants (DR, JC) were part of the 
consensus meeting alongside the south England FEO who helped to facilitate the 
contribution of parents and children in the meeting.  
 
Results 
Step 1: Identifying candidate outcomes 
Thirty seven papers were included in the review (Figure 1); 181 outcomes were recorded 
verbatim. A provisional list of 177 outcomes (Supplementary material 2) was reviewed at a 
face-to-face meeting. There were a large number of outcomes that overlapped considerably 
so outcomes were coded using the COMET taxonomy 29 in to the following domains: 
Physiological nervous system outcomes, Physical functioning, Social functioning, Role 
functioning, Emotional functioning/wellbeing, Cognitive functioning, Global quality of life 
and Adverse events/effects. Similar outcomes were discussed and aggregated in the 
meeting which resulted in 48 overall outcomes for inclusion in R1 of the Delphi survey 
(Table 1). Each outcome was given a lay domain name and description for use in the survey. 
The descriptions were agreed upon with two parent lay co-applicants at the study meeting.  
 
Step 2: Delphi survey 
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One hundred and sixty-five people registered interest through our study website. Of the 165 
interested people, 102 participants took part in R1 (professionals n=76, 75%; parents n=23, 
20%; young people n=3, 3%), and 80 from R1 completed R2 (professionals n=61, 76%; 
parents n=16, 20%; young people n=3, 4%) (Table 2). The majority of people who completed 
R2 were from London (professionals, 30%; parents and young people, 21%), with full 
demographics of participants available in supplementary material (S3). One professional 
withdrew from the study in R1 due to work commitments. Four people did not fully answer 
R1 questions and only the questions they answered were included in the analysis. Twenty-
two people did not fully complete R2 questions despite logging in and only the questions 
they answered were analysed. R1 and R2 of the Delphi was open for two weeks, with a one-
week gap in between the rounds to allow the histograms to be created and uploaded for R2. 
Forty-eight outcomes were rated in R1 (Table 1) and an additional 19 outcomes were 
suggested in R1, of which four were brought forward based on pre-defined decisions 
(Supplementary material S4). After the close of the Delphi survey, 11 outcomes met the a 
priori condition for ‘consensus in’ from R2. Delphi R1 and R2 scores are shown in Table 3. 
The attrition rate from R1 to R2 was 22% overall (33% of parents, 20% of professionals, 0% 
of Young people), displayed in Table 2.  
 
Step 3: Consensus meeting 
Nineteen people were present at the face-to-face consensus meeting and 15 were eligible 
to vote: two young people (aged 11 and 12), four parents, nine professionals (two 
paediatricians, two paediatric neurologists, two sleep consultants, one clinical psychologist, 
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one physiologist and one professor of children’s nursing) with information about meeting 
members available in supplementary material (S5). Five of the voters had not taken part in 
the Delphi survey but were deemed eligible as they had sufficient knowledge of the CHOICE 
project. 28 outcomes were voted as critical for the COS from the 41 no-consensus 
outcomes. Overall, 39 outcomes were deemed critical for inclusion in the COS split in to ten 
domains: Seizures, Sleep, Global Quality of Life, Mental Health, Social functioning, Physical 
functioning, Cognition, Behaviour, Family life and Adverse Events. An overview of the final 
COS and its development process is shown in figure 2 and the results of the consensus 
meeting in Table 4. 
 
Discussion 
This study enabled young people with epilepsy, parents and health professionals from 
different backgrounds to come together and reach consensus on important outcomes to 
measure in evaluative research in RE. The 39 outcomes included in the COS were rated as 
‘critical’ by more than 70% of people in all three stakeholder groups. Using Delphi 
methodology avoids potential over-influence of one type of stakeholder and captures 
different perspectives. Hence our COS represents the view shared by young people with 
epilepsy, parents and various health professionals working with children with epilepsy. 
Future research evaluating interventions for children with RE should use the CHOICE COS as 
a reference for selecting outcomes and consider its adaptability for other childhood 
epilepsies. 
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The CHOICE COS is the result of a transparent process that was inclusive of young people 
and parents, as well as professionals in the field of epilepsy. The 39 outcomes across 10 
domains perhaps represent more of a ‘comprehensive’ rather than a ‘core’ outcome set 
(Figure 2). A COS is meant to be a minimum set of outcomes to report. Further work could 
consider reducing the number of outcomes by ranking which outcomes are of most 
importance, relevant to each other. We did not have enough time during our face-to-face 
meeting to undertake a ranking task. The COMET handbook 25 identifies examples of where 
ranking has been used 31–33 as well as a recent study from the COMET database conducted 
in Sri Lanka that used a ranking method.10  
 
Our COS captured commonly reported items such as ‘seizure frequency’ consistent with 
existing guidelines11–16. However, in contrast, our COS highlights non-seizure related 
outcomes such as ‘school attendance’ (attending school and engaging in school curriculum) 
and ‘feelings about epilepsy’ (emotions or reactions to having epilepsy such as 
embarrassment or stigma) agreed as critical for inclusion in the COS. All COS outcomes and 
their definitions are in Table 1.  Outcomes such as ‘pain’ were not deemed as important for 
an epilepsy COS across the stakeholder groups. This might be a reflection on the relevance 
of that outcome for this specific type of epilepsy 21,34. In the consensus meeting, the young 
people involved were vocal and fairly represented, and their views were often persuasive on 
other participants. The inclusion of more child-centred outcomes suggests that the seizure-
centred view is not the only important outcome for HRQoL in young people with RE. 
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Pragmatically, to inform our trial we are identifying and assessing epilepsy-specific health 
related quality of life measures. 
 
The COMET database included a study conducted in Sri Lanka that has developed outcome 
criteria to measure effectiveness of antiepileptic therapy in children, which included young 
people with epilepsy as one of the stakeholder groups 10. The study was published whilst we 
were in the process of conducting our study. Their study recruited 15 young people with 
epilepsy, and the outcomes that reached consensus were very similar to ours, which adds 
assurance that our COS captures outcomes important to young people with epilepsy across 
different settings. For example, their work included outcomes such as frequency of seizures, 
severity of seizures, seizure freedom, cognitive function, activities that children like to do, 
school attendance, behaviour and quality of life, which map well on to the COS we propose. 
Interestingly, they ranked their outcomes with frequency of seizures being most important, 
followed by quality of life which might suggest that seizures affect QoL 10.  
 
Major strengths of the CHOICE study include a prior defined protocol 23, following COMET 
initiative methodology and using the standardised COMET taxonomy 29. The DelphiManager 
software ensured that the views of all three stakeholder groups were given equal 
representation despite varying numbers of participants in each group. The DelphiManager 
survey method ensures fair representation as analysis is assessed within stakeholder group 
before comparing across stakeholder group. This is the same method we used in the 
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consensus meeting, as we used proportions of stakeholder type to balance representation 
and compared within stakeholder group before comparing across. We included the views of 
young people with RE, their parents and professionals in the Delphi, and we convened APs 
alongside to ensure Patient Public Involvement (PPI) input at both the development and 
implementation stage of the COS.  
 
A potential limitation of our study is that we conducted a proportionate rather than a 
comprehensive systematic review. Systematic reviews are time consuming and for the 
purposes of COS development they may not generate additional outcomes for conditions 
that are common 25. We did use various databases for the review and included a wide range 
of studies; 23 we also provided opportunities for AP and survey participants to suggest any 
outcome domains not identified in the review. It is evident from the review results that such 
a large number of varied outcomes have been used in epilepsy research which 
demonstrates the important challenge of developing an agreed-upon COS. We encountered 
difficulties in recruiting RE patients to the CHOICE Delphi study, particularly that the term 
‘rolandic’ was unfamiliar to many families. Our participant information sheets and adverts 
used rolandic as well as the ILAE term ‘childhood epilepsy with centrotemporal spikes’.  
 
The CHOICE study is a work package within a larger programme of work called “Changing 
Agendas on Sleep Treatment and Learning” (CASTLE, http://castlestudy.org.uk) and 
decisions were made to reduce to two rounds rather than three in the Delphi survey to 
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deliver the COS in time to inform design of the clinical trial. The impact of this meant that 
participant burden was lessened and perhaps is a reason we had little attrition between the 
two rounds. However, a three round Delphi would have possibly meant a larger sample of 
people may have reached consensus on more items. 
 
The number of participants in our survey, particularly young people, was low in spite of our 
varied approach to recruitment. However, the three young people who took part in R1 of 
the survey also took part in R2. Attrition rates overall were good for the survey, with 78% of 
those that took part in R1 taking part in R2. This was in spite of the survey only being open 
for two weeks for each round. However, even with multiple e-mail reminders, some 
telephone calls were needed to improve the response rate. Clinical work load and school 
term time, as well as the short window that the rounds were open for, are likely to have 
contributed to the time it took for participants to respond. The number of people in each 
stakeholder group that were able to attend the consensus meeting after participating in the 
online Delphi was lower than expected based on the number invited. The meeting was held 
on a week day during school time, and parents and health professionals may have had 
different preferences for the timing of the meeting - specific needs such as clinic times for 
professionals and child care needs should be taken in to consideration for future studies. 
 
The analysis of the Delphi results grouped professionals into one stakeholder group. We 
decided to group professionals due to small numbers in some professions. However, the 
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varying roles of stakeholders may have had some influence on the level of engagement with 
a COS of children with RE. For example, the majority of professionals were epilepsy 
specialist nurses, paediatric neurologists and paediatricians and the smaller numbers were 
seen in lecturers and NHS managers. Voting in the consensus meeting was not conducted 
anonymously because we wanted to seek consensus by having active discussion about 
shared or differing opinions and for participants to consider how other stakeholders voted.  
 
The CHOICE COS focused principally on RE as an exemplar of childhood epilepsy. Focusing 
on RE avoided preferences for outcomes that might be affected by including children who 
have associated conditions such as autism or cerebral palsy. However, we consider the 
CHOICE COS could potentially be generalised across other childhood epilepsies.  Future 
work could consider the extent to which any variations might be necessary to validate the 
COS in other childhood epilepsy syndromes. The scope of our work was primarily UK based 
but the COS may have broader international relevance. In order to promote uptake of the 
suggested COS internationally, an international consensus would be needed. 
 
Having decided which outcomes to measure, the next step in the COS process is to decide 
how best to measure each of these outcomes and how to define them using published 
guidance 35. The time burden for research participants will need consideration for the 
comprehensive outcome list we currently propose. Whilst further work is necessary to 
reduce the COS and define the outcomes further, our next step will be to identify and assess 
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the measurement properties of epilepsy specific health related quality of life measures to 
inform the CASTLE trial and assess whether the outcomes we propose are measured by 
these instruments. We will consult guidelines on the selection of outcome measurement 
instruments for a COS developer by Consensus-based Standards for the selection of health 
Measurement Instruments (COSMIN) 35.  
 
Conclusions 
We recommend that future evaluative research in RE considers utilising the CHOICE COS as 
a framework for selecting outcomes for evaluative research. The CHOICE COS is a fair 
representation of the views of young people with RE, their parents and professionals views 
and has used established methodology 25. Further work to reduce the COS to a smaller 
number of outcomes by ranking will make the COS more manageable. However, we propose 
that our work towards a COS helps advance research in childhood epilepsies. We hope that 
the utilisation of outcomes suggested by this COS as a framework in future studies will 
reduce reporting bias and allow for evidence to be synthesised across different studies.  
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Figure 1. PRISMA flow chart of literature review 
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Figure 2. Overview of COS development and final COS 
  
Table 1. Outcomes used in R1 & R2 of the Delphi survey  
 
Outcome ID & name in Delphi Description Domain name 
1. Seizure freedom Not having seizures Seizures 
 
2. Seizure frequency How often seizures occur Seizures 
3. Seizure duration How long a seizure lasts Seizures 
4. Seizure severity How bad seizures are in terms of 
effects on the person during and 
after seizures - such as falls or 
injuries, incontinence, confusion, 
and time to recover afterwards 
Seizures 
5. Time to fall asleep Time it takes to fall asleep from 
snuggling down  
Sleep 
6. Time spent asleep Total time spent asleep each day Sleep 
7. Awakenings Waking in the night that 
parents/carers are aware of 
Sleep 
8. Breathing difficulties during 
sleep 
Might include snoring or gasping 
for breath 
Sleep 
9. Daytime sleepiness Feeling sleepy or actually 
sleeping during the day 
Sleep 
10. Fatigue Lacking in energy Physical functioning 
 
11. Pain Unpleasant physical sensation  Physical functioning 
12. Coordination & balance Using parts of the body together 
and efficiently, such as to ride a 
bike, or stand on one leg, 
catching and throwing 
Physical functioning 
13. Movement ability Walking, running, jumping, 
hopping 
Physical functioning 
14. Manual ability Dexterity in handling objects, 
handwriting 
Physical functioning 
  
Outcome ID & name in Delphi Description Domain name 
15. Self-care Daily routines such as eating, 
washing & dressing, toileting 
Usual activities 
16. Ability to join in activities 
with others 
Joining in with people, such as 
playing out with  
friends, doing sports, joining in 
things 
Social functioning 
 
17. Ability to play on one’s own Reading, computer etc. imaginary 
play 
Social functioning 
 
 
18. Friendships Forming and maintaining 
friendships 
Social functioning 
19. Engagement in school life Feeling part of the school 
community  
Social functioning 
 
 
20. Social life Engagement with friends and 
peers, such as going out, 
sleepovers, cinema 
Social functioning 
21. Experience of people’s 
attitudes towards epilepsy 
Bullying, social exclusion Social functioning 
22. Behaving appropriately Being able to control emotions 
and respond to situations in 
context  
Behaviour 
 
 
 
23. Impulsivity Acting without thinking Behaviour 
 
24. Fidgeting Restless, being on the go, moving 
or squirming 
Behaviour 
 
 
25. Feeling normal Feeling like other people of the 
same age 
Mental health 
26. Feelings about having 
epilepsy 
Emotions or reactions to having 
epilepsy, such as embarrassment, 
shame, stigma 
Mental health 
27. Happiness Feeling or showing pleasure or 
contentment 
 
Mental health 
  
Outcome ID & name in Delphi Description Domain name 
28. Sadness Feeling or showing sorrow or 
being unhappy 
 
Mental health 
29. Worried Being anxious or troubled about 
actual or potential problems 
Mental health 
30. Annoyed Being slightly angry or irritated 
 
Mental health 
31. Self-esteem Overall feelings about yourself Mental health 
32. Mood swings  Quick unexplained changes of 
mood 
Mental health 
 
 
33. Self-harm Thinking about hurting yourself 
on purpose or wishing you were 
dead 
Mental health 
 
 
 
34. Concealment Not telling people about epilepsy  Mental health 
 
 
35. Fears of having a seizure Having  a seizure in public, being 
injured during a seizure, dying 
during a seizure, what other 
people will do during a seizure 
Mental health 
36. Literacy Reading, writing, spelling Cognition 
37. Speech & language Making yourself understood and 
understanding when spoken to 
Cognition 
38. Memory Short & long term Cognition 
 
39. Concentration Focusing on something for the 
required period of time 
Cognition 
40. Learning Gaining new skills & knowledge 
generally 
Cognition 
 
 
41. School attendance  Attending school and engaging in 
school curriculum 
Cognition 
 
 
  
Outcome ID & name in Delphi Description Domain name 
42. Academic attainment Reaching personal potential 
through studying and completing 
assigned tasks and projects, and 
advancing to next stages of 
education 
Cognition 
43. Executive functioning The ability to plan and organise 
activities. Executive functions 
help you manage life tasks of all 
types. For example, executive 
functions let you organize a trip, 
a research project, or a paper for 
school effectively  
Cognition 
44. Overall quality of life How you feel your life is generally Global quality of life 
 
 
45. Adverse events Any unintended effects of 
treatments, side effects   
Adverse events 
46. Relationships with parents 
& siblings 
Getting along well with and 
feeling close to other members of 
family  
Family functioning 
47. Family life Impact of epilepsy on family life 
such as parent work 
opportunities and/or leisure time 
Family functioning 
48. Parent health Parent’s physical and emotional 
wellbeing 
Family functioning 
 
 
 
Outcomes suggested and included in R2 
 
Outcome ID & name in Delphi Description Domain name 
49. Unplanned epilepsy 
related admissions to 
hospital as an inpatient 
 
Unexpectedly needing to be 
admitted to hospital 
Adverse events 
  
Outcome ID & name in Delphi Description Domain name 
50. Unplanned hospital 
attendances at A&E 
Visiting the hospital due to an 
acute medical emergency 
 
 
Adverse events 
51. Attendance for medical 
appointments in 
outpatients 
Routine attendances for medical 
epilepsy management 
 
 
Seizures 
52. Drug treatment failure 
(adverse events or poor 
seizure control) 
Stopping medication because it’s 
not working or causing problems 
Adverse events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2. Response of R1 and R2 of the Delphi survey  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stakeholder group Registered 
interest 
Round 1, n(% 
who were eligible 
to take part) 
Round 2, n(% who 
were eligible to 
take part) 
 
Professionals total 120 76 (63%) 61 (80%) 
Paediatricians 51 33 (65%) 26 (82%) 
Paediatric Neurologists 16 14 (88%) 12 (86%) 
Epilepsy nurses 22 15 (68%) 12 (87%) 
Consultant in sleep 
medicine 
6 3 (50%) 2 (67%) 
Physiologists 5 4 (80%) 3 (75%) 
Respiratory & Sleep 
Physiologists 
11 3 (27%) 2 (67%) 
Dietetics lecturer 1 1 (100%) 1 (100%) 
NHS manager 2 2 (100%) 2 (100%) 
Child and adolescent 
psychiatrist 
1 1 (100%) 1 (100%) 
CEO Children’s charity 1 0 0 
Child Health Lecturer  1 0 0 
Clinical Psychologist 1 0 0 
Neuropsychologist  2 0 0 
    
Parents 40 23 (58%) 16 (67%) 
Young People  5 3 (60%) 3 (100%) 
Total 165 102 (62%) 80 (78%) 
*1 professional withdrew  
* 4 people did not answer fully in R1 
* 22 people did not fully answer in R2  
  
Table 3. R1 & R2 percentage of scores for ‘7-9’ critical across all 3 stakeholder groups 
Green highlight indicated >70% of participants rated ‘7-9’ critical. Yellow highlight indicates 
>50% of participants rated as ‘7-9’ critical. 
 
Outcome Round 1 Round 2 
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1. Seizure freedom  
 
85% 83% 67% 94% 88% 67% 
2. Seizure frequency 
 
91% 91% 67% 95% 94% 100% 
3. Seizure duration 
 
63% 87% 67% 73% 94% 100% 
4. Seizure severity 
 
77% 87% 33% 89% 100% 33% 
5. Time to fall asleep 
 
35% 22% 0% 19% 35% 0% 
6. Time spent asleep 
 55% 39% 0% 48% 71% 0% 
7. Wakings from sleep 
 59% 39% 67% 55% 76% 67% 
8. Breathing difficulties during sleep  
 54% 65% 67% 55% 75% 67% 
9. Daytime sleepiness 
 65% 39% 67% 73% 47% 67% 
10. Fatigue 
 55% 35% 33% 52% 53% 33% 
11. Pain 
 37% 57% 0% 26% 56% 0% 
  
Outcome Round 1 Round 2 
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12. Coordination & balance  
 40% 52% 100% 41% 59% 100%  
13. Movement ability 
 27% 30% 67% 26% 31% 67% 
14. Manual ability 
 31% 35% 33% 26% 47% 33% 
15. Self-care 
 42% 30% 33% 28% 41% 33% 
16. Ability to join activities with others 
 59% 48% 67% 64% 59% 67% 
17. Ability to play in one’s own 
 45% 26% 67% 36% 35% 67% 
18. Friendships 
 58% 52% 67% 62% 53% 67% 
19. Engagement in school life 
 74% 57% 67% 75% 59% 67% 
20. Social life 
 64% 52% 33% 67% 65% 33% 
21 Experience of other people’s attitudes towards epilepsy 
 49% 43% 67% 46% 50% 67% 
22. Behaving appropriately 
 56% 61% 67% 57% 71% 67% 
23. Impulsivity 
 42% 48% 67% 46% 65% 100% 
24. Fidgeting 
 38% 43% 33% 38% 65% 33% 
  
Outcome Round 1 Round 2 
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25. Feeling normal 
 68% 61% 33% 79% 65% 33% 
26. Feelings about having epilepsy  
 68% 74% 33% 70% 65% 33% 
27. Happiness 
 67% 64% 100% 79% 65% 100% 
28. Sadness 
 65% 61% 33% 66% 63% 33% 
29. Worried  
 67% 57% 67% 67% 63% 67% 
30. Annoyed 
 49% 52% 100% 46% 69% 100% 
31. Self-esteem 
 69% 65% 67% 77% 69% 100% 
32. Mood swings 
 60% 52% 67% 54% 69% 100% 
33. Self-harm 
 68% 59% 50% 70% 75% 67% 
34. Concealment 
 57% 52% 33% 49% 56% 33% 
35. Fears of having a seizure 
 74% 74% 100% 84% 81% 100% 
36. Literacy  
 57% 57% 67% 66% 81% 67% 
37. Speech & language 
 66% 57% 33% 67% 69% 33% 
38. Memory 
 72% 65% 67% 72% 81% 67% 
39. Concentration 
 72% 65% 100% 79% 81% 100% 
  
Outcome Round 1 Round 2 
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40. Learning  
 79% 74% 100% 80% 94% 100% 
41. School attendance 
 70% 48% 67% 77% 50% 67% 
42. Academic attainment  
 63% 52% 67% 72% 69% 100% 
43. Executive functioning  
 63% 48% 100% 67% 69% 100% 
44. Overall quality of life  
 92% 74% 67% 93% 88% 67% 
45. Adverse events or reactions  
 71% 78% 67% 72% 81% 67% 
46. Relationships with parents & siblings  
 58% 48% 100% 61% 63% 100% 
47. Family life  
 62% 48% 67% 64%  56% 67% 
48. Parental health  
 51% 43% 67% 46% 50% 67% 
49. Unplanned epilepsy-related admissions to hospital as inpatient* 
    70% 67% 67% 
50. Unplanned hospital attendances at A&E* 
    70% 64% 33% 
51. Attendance for medical appointments in outpatients* 
    33% 44% 0% 
52. Drug treatment failure (adverse events or poor seizure control)* 
    78% 87% 100% 
 
   
Table 4.   Summary of consensus meeting voting results   
 
Outcomes have been categories based on the follow: 
 
1. Item previously ‘consensus in’ and no discussion needed 
2. Discussed and voted in 
3. Discussed and agreed to combine with another outcome/word differently (or to be 
considered as part of the ‘how’ an outcome is measured) 
4. Agreed to not discuss further or voted as ‘not critical for the COS’ 
 
Outcome Number of 
stakeholder groups 
(out of 3) achieving 
consensus prior to 
meeting 
% of 15 meeting 
participants voting as 
critical for inclusion in 
COS 
% of meeting 
participants 
voting as not 
critical  
Category of 
meeting 
conclusion 
Seizure freedom 3 100% 0% 1 
Seizure frequency 3 100% 0% 1 
Seizure duration  3 100% 0% 1 
Seizure Severity 
 
2 100% 0% 2 
Time to fall asleep 
 
 
 
0 0 100% 4 
Time spent asleep in 24 
hours 
 
 
1 100% 0% 3 
Time spent asleep each 
night 
 
 
1 100% 0% 3 
Awakenings from sleep 
 
2 100% 0% 2 
Breathing difficulties 
during sleep  
 
2 93% 6% 2 
Daytime sleepiness 
 
2 93% 6% 2 
Fatigue 
 
 
 
0 0% 100% 4 
Pain 
 
 
 
0 0% 100% 4 
   
Outcome Number of 
stakeholder groups 
(out of 3) achieving 
consensus prior to 
meeting 
% of 15 meeting 
participants voting as 
critical for inclusion in 
COS 
% of meeting 
participants 
voting as not 
critical  
Category of 
meeting 
conclusion 
Movement ability – Gross 
Motor function 
 
 
 
 
1 100% 0 3 
Manual ability (fine 
motor function) 
 
 
 
 
1 93% 6% 3 
Self-care 0 0% 100% 4 
Ability to join in activities 
with others  
 
1 100% 0% 2 
Ability to play on one’s 
own 
1 0% 100% 4 
Friendships 
 
1 93% 7% 2 
Engagement in school life 
 
2 100% 0% 2 
Experience of other 
people’s attitudes 
towards epilepsy 
 
1 100% 0% 2 
Behavioural concerns 2 100% 0% 3 
Impulsivity 1 79% 21% 2 
Fidgeting 0 0% 100% 4 
Feelings about having 
epilepsy 
2 100% 0% 3 
Self-harm 3 100% 0% 1 
Fears of having a seizure 3 100% 0% 1 
Self-esteem 2 100% 0% 2 
Mood swings 1 100% 0% 2 
Concealment 0 100% 0% 2 
Learning 3 100% 0% 1 
Concentration  3 100% 0% 1 
Literacy 2 100% 0% 2 
   
Outcome Number of 
stakeholder groups 
(out of 3) achieving 
consensus prior to 
meeting 
% of 15 meeting 
participants voting as 
critical for inclusion in 
COS 
% of meeting 
participants 
voting as not 
critical  
Category of 
meeting 
conclusion 
Memory  3 100% 
 
0% 1 
Speech & Language 
 
0 93% 7% 2 
School attendance 2 100% 0% 2 
Academic attainment 
 
2 100% 0% 2  
Executive functioning 
 
1 100% 0% 2 
Relationships with 
parents 
& siblings 
 
1 100% 0% 2 
Family life 1 100% 0% 2 
Parental health 
 
1 100% 0% 2 
Overall quality of life  3 100% 0% 1 
Adverse events or 
reactions 
3 100% 0% 1 
Drug treatment failure 
events (adverse events or 
poor seizure control) 
3 100%  1 
Epilepsy specific  
attendance at A&E and 
or/unplanned admission 
to the ward 
2 100% 0% 3 
 
 
   
SUPPLEMENTARY 1: Systematic Review Search 
 
SEARCH LOG 1 
 
 
DATABASE DATE Number of hits 
CDSR  
 
 
28/9/17 56 
DARE  28/9/17 10 
CENTRAL 28/9/17 60 
MEDLINE 28/9/17 15 
EMBASE 28/9/17 28 
PSYCINFO 28/9/17 5 
CINAHL 28/9/17 4 
 
TOTAL: 147 
DUPLICATES REMOVED: 33 
NUMBER FOR REVIEW: 114 (RCTs 56; potential SRs 58) 
 
Search strategies 
 
Cochrane Library databases  
 
CENTRAL 
 
Search Name: Epilepsy outcomes 
Date Run: 28/09/17 09:37:42.862 
Description:   
 
ID Search Hits 
#1 MeSH descriptor: [Epilepsy, Rolandic] explode all trees 14 
#2 rolandic:ti,ab  40 
#3 BCECTS:ti,ab  2 
#4 "centro temporal spikes":ti,ab  3 
#5 "centrotemporal spikes":ti,ab  24 
#6 (child* near/3 epilep*):ti,ab  611 
#7 #1 or #2 or #3 or #4 or #5  62 
 
CDSR/DARE 
 
Search Name: Epilepsy outcomes 
Date Run: 28/09/17 09:37:42.862 
Description:   
 
ID Search Hits 
#1 MeSH descriptor: [Epilepsy, Rolandic] explode all trees 14 
   
#2 rolandic:ti,ab  40 
#3 BCECTS:ti,ab  2 
#4 "centro temporal spikes":ti,ab  3 
#5 "centrotemporal spikes":ti,ab  24 
#6 (child* near/3 epilep*):ti,ab  611 
#7 #1 or #2 or #3 or #4 or #5  62 
#8 #1 or #2 or #3 or #4 or #5 or #6  643 
 
 
MEDLINE 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     Epilepsy, Rolandic/ (543) 
2     rolandic.ti,ab. (1530) 
3     BCECTS.ti,ab. (53) 
4     centro temporal spikes.ti,ab. (119) 
5     centrotemporal spikes.ti,ab. (384) 
6     1 or 2 or 3 or 4 or 5 (1952) 
7     systematic.ti. (99433) 
8     (systematic* adj2 review*).ab. (92392) 
9     systematic overview.ti,ab. (845) 
10     evidence synthesis.ti,ab. (2775) 
11     (medline or pubmed).ab. (147225) 
12     7 or 8 or 9 or 10 or 11 (229623) 
13     6 and 12 (15) 
 
EMBASE 
 
Database: Embase <1974 to 2017 September 27> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     rolandic epilepsy/ (726) 
2     rolandic.ti,ab. (2129) 
3     BCECTS.ti,ab. (89) 
4     centro temporal spikes.ti,ab. (194) 
5     centrotemporal spikes.ti,ab. (552) 
6     1 or 2 or 3 or 4 or 5 (2835) 
7     "systematic review (topic)"/ (22189) 
8     systematic.ti. (114424) 
9     (systematic* adj2 review*).ab. (113048) 
10     systematic overview.ti,ab. (887) 
11     evidence synthesis.ti,ab. (3064) 
12     (medline or pubmed).ab. (176528) 
13     7 or 8 or 9 or 10 or 11 or 12 (286135) 
14     6 and 13 (28) 
   
 
PsycINFO 
 
Database: PsycINFO <1806 to September Week 4 2017> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     rolandic.ti,ab. (492) 
2     BCECTS.ti,ab. (29) 
3     centro temporal spikes.ti,ab. (42) 
4     centrotemporal spikes.ti,ab. (136) 
5     1 or 2 or 3 or 4 (616) 
6     systematic.ti. (18146) 
7     (systematic* adj2 review*).ab. (18292) 
8     systematic overview.ti,ab. (221) 
9     evidence synthesis.ti,ab. (424) 
10     (medline or pubmed).ab. (16611) 
11     6 or 7 or 8 or 9 or 10 (36715) 
12     5 and 11 (5) 
 
CINAHL 
 
Search 
ID#  Search Terms  
Actions  
S15  S6 AND S14   View Results (4)  
View Details  
Edit   
S14  S7 OR S8 OR S9 OR S10 OR S11 
OR S12 OR S13   
View Results (101,022)  
View Details  
Edit   
S13  AB medline or pubmed   View Results (43,843)  
View Details  
Edit   
S12  TI ( metasynthesis or meta-
synthesis ) OR AB ( 
metasynthesis or meta-
synthesis )   
View Results (661)  
View Details  
Edit   
S11  TI evidence synthesis OR AB 
evidence synthesis   
View Results (1,611)  
View Details  
Edit   
S10  TI (systematic N2 overview) OR 
AB (systematic N2 overview)   
View Results (397)  
View Details  
Edit   
True S15
True S14
True S13
True S12
True S11
True S10
   
S9  TI (systematic* N2 review*) OR 
AB (systematic* N2 review*)   
View Results (60,487)  
View Details  
Edit   
S8  TI systematic   View Results (44,192)  
View Details  
Edit   
S7  (MH "Systematic Review")   View Results (42,512)  
View Details  
Edit   
S6  S1 OR S2 OR S3 OR S4 OR S5   View Results (138)  
View Details  
Edit   
S5  TI centrotemporal spikes OR AB 
centrotemporal spikes   
View Results (41)  
View Details  
Edit   
S4  TI "centro temporal spikes" OR 
AB "centro temporal spikes"   
View Results (11)  
View Details  
Edit   
S3  TI BCECTS OR AB BCECTS   View Results (5)  
View Details  
Edit   
S2  TI rolandic OR AB rolandic   View Results (98)  
View Details  
Edit   
S1  (MH "Epilepsy, Rolandic")   View Results (1)  
View Details  
Edit  
 
 
 
 
 
True S9
True S8
True S7
True S6
True S5
True S4
True S3
True S2
True S1
  
SUPPLEMENTARY 2 – Characteristics of included papers and Provisional list of outcomes 
Table S2.1 - Characteristics of included papers 
 
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
1 Baca, C. B., et al. 
(2011).  
 
(1) 
Observational 
 
Prospective, community-
based cohort study of newly 
diagnosed childhood 
epilepsy, with ongoing 
prospective follow up.  
• 277 children  
129 females, 148 males. 
• Mean age: 13 range: 8-17 
• New diagnosed epilepsy, 
unprovoked seizure between 28 
days and 15 years. 
 
Health related quality of life 
 
 
Cognitive function 
Child health questionnaire (CHQ)  
 
 
Neurologic medical records, parent 
interviews, school records, and 
standardized neuro-psychological testing 
using the Wechsler Intelligence Scale for 
Children. 
2 Baca, C. B. et al., 
(2012) 
 
(2) 
Observational 
 
Prospective community-
based study of long-term 
outcomes of childhood-onset 
epilepsy. (The Connecticut 
Study of Epilepsy). 
• 277 parent-child dyads  
• Mean age of child: 5.1, SD: 2.5. 
• Newly diagnosed childhood 
epilepsy. 
Health related quality of life Child health questionnaire (CHQ) 
3 Bast et al., 
(2003)  
 
(3) 
Systematic Review (SR) 
 
SR of the influence of 
sulthiame on EEG in BECTS 
• 66 children  
• Diagnosis of BECTS  
• Mean age: 8.3, range 3-10 years 
 
The rate of treatment failure 
events 
 
 
EEG 
Any first seizure 
 
 
 
EEG  
4 Benson, A., et 
al. (2016) 
 
(4) 
Qualitative 
 
Mixed qualitative & 
quantitative in 2 stages. 
Phase one: qualitative 
exploratory design using 
semi-structured interviews. 
 
Phase 2: 
Questionnaires/cross-
sectional survey  
Phase one: 
• 33 Children aged 6-16 years, 
mean age: 7.33 and 40 parents. 
• Prescription of anti-epileptic 
medication 
 
Phase two:  
• 47 children aged 8-18 years; 
mean age 13.19, and 72 
parents. 
 
Themes:  Social exclusion in 
epilepsy, Activity restrictions, 
Teasing/bullying, concealment, 
stigma coaching  
 
 
Stigma 
Interview 
 
 
 
 
 
Child Stigma Scale (CSS) 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
5 Borggraefe et 
al., (2013) 
 
(5) 
Randomised Controlled Trial 
(RCT) 
 
Randomised, double-blinded 
controlled trial (over 26 
months). Non inferiority trial 
of LEV (Levetiricetam) 
compared to STM 
(Sulthiame). Randomly 
allocated to the LEV or STM 
treatment arm. 
 
 
• 44  children between 6-12 years 
of age  
• Diagnosis of BECTS 
• LEV group (n=21): mean age: 
8.7, 6 females 
 
• STM group (n=22): mean age: 
9.0, 10 females 
Primary endpoint: occurrence of a 
treatment failure event   
 
 
 
 
 
 
Dropouts related to adverse 
events/occurrence of a drug 
related adverse reaction 
Occurrence of a seizure during the 
observation period – 24 weeks after 
reaching target dose. 
 
 
 
 
 
Adverse events e.g. general symptoms, 
pain etc.  
Urine analysis 
6 Chong et al. 
(2016)  
 
(6) 
SR of Qualitative Studies  
 
Systematic review of 
qualitative 
studies on the experiences of 
children and adolescence. 
• 951 participants overall. 
• Participants aged 3-21 years 
• Diagnosed with epilepsy.  
Themes:  Loss of Bodily Control:  
Being overtaken, Susceptibility to 
physical harm, Fragility of the 
brain, Alertness to mortality, 
Bodily powerlessness, Loss of 
Privacy: Declarative Disease, 
Humiliating Involuntary Action, 
Unwanted special attention, Social 
embarrassment of medicine 
taking, Inescapable inferiority and 
discrimination: 
Vulnerability to Prejudice, 
Consciousness of abnormality,  
Limiting social freedom, 
Therapeutic Burden and Futility:  
Awaiting a Fabled Remission, 
Overwhelming Life Disruption, 
Social and spiritual connectedness 
Interview 
7 Connock et al., 
(2006). 
 
(7) 
SR 
 
SR to examine the clinical  
effectiveness and cost-
effectiveness  
• Young people with epilepsy 
under 18 years old and mixed 
age groups with epilepsy if 
including persons less than 18 
years old. 
Premature discontinuation due to 
adverse events 
 
 
Seizure frequency  
Adverse events e.g. vomiting, infection, 
headache, fever. 
 
 
The number of seizures during 
maintenance  
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
of newer anti-epileptic drugs 
(AEDs) for  
epilepsy in children. Drugs 
included: gabapentin,  
lamotrigine, levetiricetam, 
oxcarbazepine,  
tiagabine, topiramate and 
vigabatrin. 
8 Coppola et al., 
(2007) 
 
(8) 
RCT 
 
Randomised to levetiricetam 
(LEV) group, 
and an Oxcarbazepine (OXC) 
group.  
 
LEV & OXC – 5mg/kg – up to 
a  
daily maximum dose of 20 
mg/kg.   
 
• 39 children aged between 3.3 to 
14 years (m: 8.4) were 
randomised to receive 
monotherapy with LEV 
levetiricetam or OXC.  
• New diagnosis of BECTS 
according to ILAEO, absence of 
neurological and mental deficits. 
 
Complete seizure freedom 
 
 
 
 
Awake & sleep EEG 
Seizure freedom (recorded in an 
epilepsy diary) 
 
 
 
EEG 
9 Smith et al., 
(2015) 
 
(9) 
Meta-Analysis 
 
Evaluation of 22 studies of 
literacy and/or language skills 
in children with rolandic 
epilepsy, published after 
2000. 
• Children and adolescents with 
rolandic epilepsy, aged 5-18 
years.  
 
Language & Literacy 
 
 
Reading measured with: 
GORT accuracy (Gray, Oral, Reading 
Tests), WIAT (Weschsler Individual 
Achievement Test),  WRAT (Wide Range 
Achievement Test) 
 
Phonological processing  
measured with: TOWRE (rest of word 
reading efficacy) 
 
Expressive language 
measured with: CELF (Clinical Evaluation 
of Language Fundamentals) 
 
Receptive language 
measured with: CELF, Peabody Picture 
Vocabulary Test (PPVT)  
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
10 Gutter et al., 
(2013) 
 
(10) 
Observational 
 
Purpose of study were to 
explore the prevalence of 
sleep disturbances in a large 
cohort of school-age children 
with partial epilepsy.  
• 131 children – partial epilepsy 
aged 4 to 10 years and 161 age 
and sex matched controls. 
Sleep 
 
 
 
 
 
 
 
 
 
 
Restrictions in childhood epilepsy  
 
 
 
School environment/Peers & social 
support/autonomy & parent 
relations/psychological 
wellbeing/physical wellbeing 
Sleep Disturbance Scale  
for children (SDSC), Medical Outcomes 
 Study-Sleep Scale (MOSS –S) and 
Groningen  
Sleep Quality Scale (GSQS)  
Hague Seizure Severity Scale (HSSS), the 
Hague  
Side Effects Scale (HaSES) and  
 
 
 
Hague Restrictions in Childhood Epilepsy 
Scale (HaRCES)  
 
 
Kidscreen-27 
 
 
 
11 Kim et al., 
(2015) 
 
(11) 
Observational 
 
Investigate cortical thickness 
and gray matter volume 
abnormalities in BECTS. 
• 20 children (14 males, mean age: 
7.5),  
• Newly diagnosed BECTS 
 
EEG 
 
Cortical thickness/grey matter 
 
 
EEG  
 
MRI 
12 Lewis et al., 
(2008) 
 
(12) 
Observational 
 
E-survey and interviews  
 
 
• 44 children and young people 
with epilepsy aged 3-23 (parent 
responses on behalf of child).  
• Interviews with a separate group 
of 22 children and young people 
with  epilepsy. 
Impact of epilepsy on school E-survey 
13 Liu et al., (2016) 
 
(13) 
RCT 
 
Children were randomised 
into two groups Group 1: 
topiramate once every night 
 
• 85 children  
• 54 males and 31 females 
aged from 3.3 years to 13 years.  
Diagnosed with benign 
childhood epilepsy  
 
EEG 
 
Seizure frequency 
 
 
Adverse events 
EEG 
 
Parent recorded 
 
 
Parent recorded/physiological measures 
of blood, urine. 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
Group 2: topiramate twice a 
day. 
14 Loiselle et al., 
(2016) 
 
(14) 
Observational  
 
Trajectories  
of health-related quality of 
life  
(HRQOL) among children with 
 newly diagnosed epilepsy, 
and  
evaluate key predictors of 
HRQOL  
trajectories.  
 
• 120 children with epilepsy and 
their care giver 
• 2-12 years old, received an 
epilepsy diagnosis on day of 
study recruitment 
Paediatric epilepsy side-effects 
 
 
 
 
 
Health-related quality of life 
 
 
 
 
Parental fears about the impact of 
a child’s seizures on functioning 
Paediatric Epilepsy Side Effects  
Questionnaire (PESQ)  
(Mortia et al., 2012).  
 
 
 
Care-giver proxy report  
version of the PedsQL 4.0  
(Varni, Seid & Kurtin, 2001).  
 
 
The Parent Report of Psychosocial Care  
(Austin, Dunn, Huster & Rose, 1998) – 
 Includes the five-item Concerns and  
Fears subscale (assesses parental 
 fears about the impact of the 
 child’s seizures on functioning  
and outcomes) 
15 Melchionda et 
al., (1999) 
 
(15) 
 
Observational 
 
Evaluate long term evolution 
of headaches associated with 
rolandic centrotemporal 
spikes 
 
• 32 children with rolandic centro 
temporal spikes 
Headache Occurrence of symptom 
16 Mitsudome et 
al., (1997 
 
(16) 
Observational 
 
Effectiveness of clonazepam 
on rolandic discharges. 
 
• 32 children with centro temporal 
spikes (CTS)  that has episodes of 
headache  (16 females) with 
centro-temporal spikes (CTS) at 
EEF 
• 52 matched controls  
 
EEG EEG 
17 Moffat et al., 
(2009) 
 
Observational 
 
• 22 children (11 male, 11 female)  
• Mean age; 9, Range: 7-12  
Themes: Impact on social life, 
developmental/role related issues, 
psychological epilepsy related 
Interview 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
(17) Impact of childhood epilepsy 
on quality of life 
 
• Experiences partial seizures and 
some generalised seizures.  
 
issues, peer acceptance, school-
related issues, academic impact, 
family reactions, adjustment, 
compliance, seizure experience, 
fear, coping, the future, 
translational periods, medical 
experiences, emotional impact  
18 Nevitt et al., 
(2016) 
 
(18) 
SR 
 
 
RCT’s with a comparison of  
carbamazepine monotherapy  
with phenobarbitone 
monotherapy  
in individuals with epilepsy 
 
• Children or adults with partial 
onset seizures  
• Individuals with a new diagnosis 
of epilepsy 
Seizures 
 
 
Adverse events 
 
 
 
IQ 
 
Memory 
Incidence of seizures 
 
 
Side effects, withdrawals, incidence of 
allergic reactions 
 
 
WISC-R Scale, Bender-Gestalt test 
 
 
19 Rating et al., 
(2000) 
 
(19) 
RCT 
 
Children were randomized  
to receive either STM or a 
placebo 
 
• 66 children 
• Aged between 3-10 years 
• Diagnosis of BECTS (or has 2 ore  
 
Adverse events Adverse event 
20 Reilly et al., 
(2015) 
 
(20) 
 
Observational 
 
Factors associated with 
quality of life in childhood 
epilepsy.  
• Children recruited from the 
CHESS study (identification of 
children with ‘active’ epilepsy 
born between 1995 and 2007’.  
• Children aged 5-15 years 
 
Quality of life  QOLCE US  
21 Ronen et al., 
(1999) 
 
(21) 
Observational/qualitative 
 
Identifying the attributes 
of Health related quality of 
life (HRQOL) in childhood 
epilepsy.   
 
• 29 children and their parents  
• Mean age: 9.2 
• Simple/complex partial seizures 
Themes: Experience of epilepsy, 
life fulfilment/time use, home 
activities, school issues, and 
activities, social experiences, 
impact of epilepsy  
Interview  
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
22 Sajobi et al., 
(2017) 
 
(22) 
Observational 
 
Trajectories across health 
related quality of life 
domains in children with new 
onset epilepsy 
 
• 373 children with new-onset 
epilepsy 
Family life event changes 
 
 
Family functioning/resources 
 
 
 
Health-related quality of life 
 
 
Epilepsy severity 
 
 
The Family Inventory of Life Event 
Changes (FILE) 
 
Family inventory of resources and 
management (FIRM) 
 
 
QOLCE-55 
 
 
Global Assessment of Severity of 
Epilepsy (GASE) 
 
The Family adaptability, partnership, 
growth, affection and resolve (APGAR) 
23 Schmitt et al., 
(2009) 
 
(23) 
Observational  
 
Effects of valproic acid on 
sleep in children with 
epilepsy 
 
• 46 children 
• Aged 1.7-17.4 years, mean 8.4 
• History of generalised epilepsies  
Sleep Sleep habits survey 
24 Schraegle et al., 
(2016) 
 
(24) 
Observational  
 
Executive functioning and 
HRQOL in childhood epilepsy 
• 130 children 
• Mean age: 11.6 years, SD: 3.6 
years 
• Epilepsy diagnosis 
 
Executive functioning 
 
 
Behaviour  
 
Memory 
 
Intelligence 
 
 
HRQOL 
Behaviour rating inventory of executive 
functioning (BRIEF)  
 
BRIEF 
 
BRIEF 
 
Wechsler Intelligence Scales (WSI-II) 
(WISC-IV) 
 
Quality Of Life in Childhood Epilepsy 
scale (QOLCE) 
25 Seidel et al., 
(1999) 
 
(25) 
Observational 
 
• 27 Children  
• 12 diagnosed with benign 
rolandic epilepsy or migraine 
headache, 15 with migraine 
Intelligence 
 
 
Language 
Wechsler Intelligence Scale for Children 
3rd edition 
 
Boston Naming Test 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
Cognitive and behavioural 
effects of carbamazepine in 
rolandic children. 
• Mean age BECTS: 9.7, aged 
between 6-12 years 
 
Memory 
 
 
Motor skills 
 
 
Behaviour 
 
Wide Range Assessment of Memory and 
Learning  
 
Finger tapping test, Grooved pegboard 
test 
 
Child behaviour checklist (CBCL) 
26 Stafstrom et al., 
(2012) 
 
(26) 
Observational 
 
Art therapy focus groups for 
young people with epilepsy 
• 16 children, mean age: 12.8 
years, SD: 2.9 
• Range of childhood epilepsies 
including rolandic 
Self-concept  
 
 
 
 
 
 
 
Attitude towards epilepsy 
 
 
 
 
Impact of epilepsy 
 
 
 
 
Piers-Harris Children’s Self-Concept 
Scale 2 
 
Art therapy assessments (Seizure 
drawing task, Formal Elements Art 
Therapy Scale/Picking an Apple from a 
Tree, Levick Emotional and Cognitive Art 
Therapy Assessment) 
Child Attitude Towards Illness Scale 
(CATIS) 
 
 
 
Impact of Childhood Neurologic 
disability scale (ICNDS)/ Impact of 
Paediatric Epilepsy Scale (IPES) 
 
 
27 Tacke et al., 
(2016) 
 
(27) 
RCT  
 
Children with BECTS 
Randomly allocated to LEV or  
STM treatment group.  
 
• 44  children 
• Aged between 6 and 12 years of 
age 
• Diagnosis of BECTS 
Memory Number recall test from the Kaufman 
assessment battery for children (K-ABC), 
Verbal learning memory test (CLMT), 
culture free intelligence test (CFT-R)  
28 Tan et al., 
(2014) 
 
(28) 
SR 
 
Review of antiepileptic drug 
RCT in children with BECTS  
 
• 262 children up to the age of 15 
years 
• Diagnosis of BECTS  
Proportion of patients seizure free 
at 3 & 12 months 
 
 
Adverse event 
Proportion of patients seizure free at 3 & 
12 months 
 
 
Adverse event 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
29 Tedrus et al., 
(2006) 
 
(29) 
 
Observational  
 
EEG and intelligence in 
children with BECTS 
• 26 children aged 8-11 years old 
(10 female, 16 male) & a paired 
control group 
• Diagnosis of BECTS  
 
Intelligence  
 
 
 
 
EEG 
Wechsler Intelligence Scale for Children 
(WISC-III) 
 
 
 
EEG 
30 Turky et al., 
(2008) 
 
(30) 
Observational 
 
Epidemiological study aimed 
at determining the 
prevalence of behavioural 
and emotional 
problems in a UK community-
based population of  
children and adolescents 
with epilepsy  
• 56 children and adolescents with 
epilepsy aged 4-17.  
• 25 males, 31 females. 
• Diagnosis of epilepsy, age at 
epilepsy onset: 6 years old.  
 
 
 
Strengths & difficulties  
 
 
Seizure severity 
 
 
Moods, feelings & emotions 
 
 
Impact of paediatric epilepsy  
 
 
Quality of life in epilepsy 
Strengths & difficulties questionnaire 
(SDQ) 
 
Revised Liverpool Seizure Severity Scale  
 
 
The Moods and Feelings Questionnaire 
(MFQ) 
 
The Impact of Paediatric epilepsy scale 
(IPES)  
 
Quality of Life in  Epilepsy Inventory for 
Adolescents (QOLIE-AD-48) 
31 Turner et al., 
(2004)  
 
(31) 
Observational 
 
Prospective, randomized, 
single-blinded, 
crossover, placebo-
controlled, pilot clinical  
trial investigating exposure to 
music on EEG  
of children with BECTS. 
 
• 4 children aged 5-9 years, were 
selected from EEGs diagnostic of  
BECTS 
 
Interictal epileptiform discharges 
(IED) 
EEG 
32 Verhey et al., 
(2009) 
 
(32) 
Observational 
 
QOL in children with epilepsy 
and agreement between 
child and parent 
• Children aged 8-17 years were 
included with a diagnosis of 
active epilepsy  
• 375 children and 378 parents  
 
Health related quality of life  CHEQOL-25  
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
33 Wille et al., 
(2010) 
 
(33) 
Preference based/HRQOL 
measure 
 
Development of the EQ-5D-Y 
• Epilepsy measure designed for 
young people 
Mobility 
 
Looking after myself 
 
Usual activities 
 
Pain/discomfort and feeling 
worried 
 
Sad or unhappy 
EQ-5DY 
34 Stevens et al., 
(2011) 
 
 
(34) 
Preference based/HRQOL 
measure 
 
Development of the Child 
Health Utility (CHU9D) 
• 247 children recruited from 
general and clinical paediatric 
populations tested 
Sad 
 
Pain 
 
Tired 
 
Annoyed 
 
School Work  
 
Sleep 
 
Daily routines and activities 
 
 
CHU9D 
35 Feeny et al., 
(2002) 
 
(35) 
Preference based/HRQOL 
measure 
 
Development of the Health 
Utilities  Index Mark 3 (HUI3) 
• A random sample of the general 
population (≥16 years of age) in 
Hamilton, Ontario, Canada 
completed preference surveys 
 
Vision 
 
Hearing 
 
Speech 
 
Ambulation 
 
Dexterity 
 
Emotion 
 
HUI3 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
Cognition 
 
Pain 
36 Mulhern et al., 
(2012) 
 
 
(36) 
 
Preference based/HRQOL 
measure 
 
NEWQoL-6D 
Epilepsy measure designed for adults 
• Used sample of 1611 
respondents with newly 
diagnosed epilepsy from SANAD 
study to generate classification 
system 
Worry about attacks 
 
Depression 
 
Memory 
 
Concentration 
 
Stigma 
 
Control 
NewQol-6d 
37 Sadeghi et al., 
2014 
 
 
(37) 
 
 
SR of outcome measures Conceptual analysis – no participants 
 
Conceptual/theoretical analysis – no 
participants 
 DISABKIDS (Epilepsy Module) 
 
ECQ (Epilepsy and children 
questionnaire) 
 
ELQOL (epilepsy and learning disabilities 
quality of life) 
 
EFA (Epilepsy Foundations of American 
Concerns Index) 
 
Glasgow Epilepsy Outcome Scale (GEOS-
C) 
 
ICI (Impact of Childhood Illness) 
 
ICNDS (Impact of Childhood Neurologic 
Disability) 
 
IPES (Impact of Paediatric epilepsy scale) 
 
QOLCE  
 
  
Study 
no. 
Author (year) 
& (Reference 
no.) 
Type of study/study 
design 
Sample characteristics Outcome domains Outcome measures 
QOLIE-AD 
 
QOLPES (Quality of life in paediatric 
epilepsy) 
 
PedsQL 
 
Neuro-QOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S2.2 - Provisional list of outcomes identified from systematic review and provided to the team 
 
 
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Physiological: Nervous 
System Outcomes 
Seizures Seizure remission Proportion seizure free 
 
Proportion of patients who are seizure free at 3 
months, 12 months 
 
Complete seizure freedom 
8, 18, 28 
 
28 
 
 
8 
  Seizure frequency Seizure frequency 
 
Seizure frequency and severity 
 
Mean seizure frequency per month 
7, 13, 18 
 
11 
 
18, 20 
 
 
  Seizure duration Mean seizure duration 20, 18 
 
 
  Seizure severity Seizure severity 
 
Severity of epilepsy 
10, 22, 30, 37 
 
24, 22 
 
 
  Seizure control Seizure control 18 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Physical Functioning  Sleep Sleep duration Overall sleep 
 
Sleep start time & end 
 
Assumed sleep per night 
 
Actual sleep per night 
 
Assumed sleep per nap 
 
Actual sleep time per nap 
 
No. of hours of sleep  
 
Nap per day 
 
Sleep 
10 
 
23 
 
23 
 
23 
 
23 
 
23 
 
10 
 
23 
 
34 
  Sleep quality Disorders of initiating and maintaining sleep 
 
Sleep breathing disorders 
 
Sleep quality 
 
Sleep hyperhidrosis 
 
Sleep disturbance/insomnia 
 
Disorders of arousal 
 
Sleep-wake transition disorders 
 
Breathing problems/headache in sleep 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10, 23 
 
10 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
  Sleep efficiency Sleep adequacy 
 
Morningness/eveningness 
10 
 
23 
 
 
  Daytime sleepiness Sleepiness 
 
Disorders of excessive somnolence 
 
Daytime somnolence 
 
Energy/fatigue 
 
Tired 
23 
 
10 
 
10 
 
20, 37 
 
34 
 
 Physical health Pain Bodily pain/discomfort 
 
Pain/discomfort – feeling worried 
 
Pain 
 
 
1, 2 
 
33 
 
34, 35, 37, 
 
 
  Physical functioning Physical functioning   
 
Physical restrictions 
 
Physical wellbeing 
 
Physical impact of epilepsy 
 
Role/social limitations physical 
 
Change in health 
 
1, 14, 22, 30, 37 
 
10, 20, 37  
 
10 
 
21 
 
1, 2 
1, 2, 37 
 
37 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Physical health  
 
 Manual ability Manual ability Mobility 
 
Ambulation 
 
Dexterity 
 
Motor skills 
33 
 
35 
 
35 
 
25 
 
 
Social Functioning Usual activities Usual activities 
 
Usual activities 
 
 
33 
 
 
  Recreation & Leisure Activity restrictions 
 
Social activities 
 
4 
 
20, 37 
  Self-care Looking after self  
 
Independence 
33 
 
37 
 
 
 Behaviour Behaviour Behaviour 
 
Behavioural regulation 
 
Internalizing behaviour 
 
Externalizing behaviour 
 
Self-concept: behavioural adjustment 
 
Conduct problems 
1, 2, 30, 24 
 
24 
 
25 
 
25 
 
26 
 
30 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
 
Prosocial behaviour 
 
Peer problems 
 
Parental ratings of behaviour 
 
Social behaviour 
 
Social health: sociability 
 
Social health: social role performance 
 
Role/social limitations: behavioural 
 
30 
 
30 
 
25 
 
30, 37 
 
37 
 
37 
 
1, 2 
 
 
 
  Family functioning & cohesion Family cohesion 
 
Family activities 
 
Family resources 
 
Parent impact – time/emotion 
 
1, 2 
 
1, 2 
 
22 
 
1, 2, 37 
 
 
 
  Educational participation School environment 10, 14 
 
 
 Social Social life/Engagement with friends 
& peers 
Social exclusion in epilepsy 
 
Teasing/bullying 
 
4 
 
4, 21 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Social embarrassment of medicine taking 
 
Limiting social freedom 
 
Social life 
 
Social interactions 
 
Peers & Social support 
 
Social functioning 
 
Social interactions 
 
Peer problems 
 
Social support 
 
Interpersonal/social 
 
Teasing/bullying 
 
Communication 
 
Social impact of epilepsy/Impact on social activities 
 
 
6 
 
6 
 
17 
 
20, 37 
 
10 
 
14, 22, 30, 37 
 
20, 37 
 
30 
 
30, 37 
 
32, 37 
 
4, 21 
 
26, 30, 37 
 
37 
 
 
  Stigma Social embarrassment of medicine taking 
 
Inescapable inferiority and discrimination: 
vulnerability to prejudice  
 
Unwanted special attention 
 
6 
 
6 
 
 
6 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Stigma 
 
 
4, 36, 37, 20, 30 
 
 
 
Role functioning Family relationships Autonomy & relationships with 
parents 
Family relationships & functioning 
 
Autonomy & parent relations 
 
Family life event changes 
 
Autonomy 
 
Family 
 
Impact of epilepsy on relationships with family, 
peers and siblings 
 
22, 37 
 
10 
 
22 
 
NF 
 
NF 
 
37 
 
 
 
Emotional 
functioning/wellbeing 
Mental Health Behavioural difficulties Behavioural difficulties 30 
 
  Depression Depression 
 
Sad 
 
Sad or unhappy 
 
20, 23, 36, 22, 34, 33 
 
34 
 
33 
  Anxiety Anxiety 20, 37 
 
  Self-esteem Self-esteem 
 
Over-all self-concept 
 
Self-concept: physical appearance and attributes 
1, 2, 20, 37 
 
26 
 
26 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
  Mental wellbeing Mental health 
 
Psychological wellbeing 
 
Emotional control 
 
Self-concept: happiness & satisfaction 
 
Moods, feelings and emotions (over 2 weeks) 
 
Mood/Mood state 
 
Intrapersonal/emotional 
 
Annoyed 
 
Emotion 
 
Optimism 
 
Emotional functioning 
 
Attitude towards epilepsy 
 
Fear of seizures 
 
Psychological functioning 
 
Control/helplessness 
 
Impact of epilepsy (psychosocial)  
 
Emotional disorders 
 
1, 2 
 
10 
 
24 
 
26 
 
30, 37 
 
37 
 
32 
 
34, 37 
 
35 
 
37 
 
37 
 
26, 30, 37 
 
NF 
 
14 
 
20, 37 
 
30, 26 
 
30 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Role/social limitations emotional 
 
Epilepsy impact: effects of epilepsy and 
antiepileptic medications 
 
Disclosure & normality 
 
 
1, 2 
 
30 
 
 
6, 32, 37 
  Secrecy Secrecy 
 
Concealment 
 
 
32, 4 
 
4 
  Fears about epilepsy Parental fears about the impact of a child’s seizure 
 
Worries/concerns 
 
Concerns about epilepsy 
 
Future worries 
 
Fear of seizures 
 
Parental concern 
 
Impact of seizures 
 
Prospects for the future 
 
 
14 
 
32, 34, 36, 37 
 
37 
 
37 
 
37 
 
37 
 
37 
 
37 
     
Cognitive Functioning Cognition Language & Literacy Reading 
 
Phonological processing 
9 
 
9 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
 
Expressive language 
 
Receptive language 
 
Speech 
 
9, 20, 25, 37 
 
9, 20, 25, 37 
 
35 
 
 
  Memory Memory 
 
Working memory 
18, 22, 30, 25, 27, 30, 36, 37 
 
24 
 
  Intelligence IQ scores 18, 24, 25, 29 
 
 
  Concentration Attention/concentration 
 
Hyperactivity/inattention 
20, 30, 36, 25, 37 
 
30 
 
 
  Executive functioning Metacognitive index 
 
Planning/organisation 
 
Executive functioning (Global executive composite) 
 
 
24 
 
24 
 
24 
  Cognition Speeded visual search and mental flexibility 
 
Cognition 
 
Cognitive function 
 
Control 
25 
 
35 
 
1, 37, 22 
 
36 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
 
Cognitive effects of epilepsy 
 
Applied cognition: general concerns 
 
Speeded visual search and mental flexibility 
 
Other cognitive 
 
 
 
 
37 
 
37 
 
25 
 
37 
 
 
 
  School performance Self-concept: Intellectual and school status 
 
School/scholastic functioning 
 
Education 
 
Impact of epilepsy on academic achievement 
 
Impact of epilepsy on school  
 
Academic self-concept: 
 
 
26 
 
37 
 
37 
 
37 
 
10 
 
26 
Global quality of life Global quality of life Global quality of life Global general health  
 
General health perceptions 
 
Impact of epilepsy on health 
 
General/overall health 
 
Overall impact of epilepsy 
 
1, 2, 14, 20, 22, 30, 32, 37 
 
1, 2, 30, 37 
 
37 
 
37 
 
37 
 
  
COMET Taxonomy 
 
Outcome Domain Aspects of health Outcome identified verbatim in individual study Study number of papers 
retrieved from systematic 
review (See Table 1) 
Total impact of childhood neurologic disability 
 
Health related quality of life 
37 
 
14, 20, 30, 32, 37 
 
 
 
Adverse events/effects Adverse events Unintended adverse events Routine urine test 
 
Liver and renal function 
 
Weight 
 
Routine blood test 
 
Paediatric epilepsy side effects 
 
Adverse events 
 
Anti-epileptic drug side effects 
 
Seizure effects 
 
Headache 
 
Hearing 
 
Vision 
 
Safety/injury 
13, 5 
 
13 
 
13 
 
13 
 
14, 18, 10 
 
18, 19, 28, NF, 5, 7, 13, 15, 30, 35, 
37, 11 
37, 10 
 
37 
 
15 
 
35 
 
35 
 
37 
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SUPPLEMENTARY 3 –  
S3.1 -  Demographics of participants from R2 of the Delphi survey 
 
Characteristic N (%) 
Professionals  61  (100) 
Place of residence in UK  
North East  3 (5) 
North West  1 (2) 
Yorkshire and The Humber 4 (7) 
East Midlands 2 (3) 
West Midlands 3 (5) 
East of England 2 (3) 
London 18 (30) 
South East 5 (8) 
South West 9 (15) 
Scotland 3 (5) 
Wales 5 (8) 
Ireland 4 (7)  
Outside UK 2 (3)  
  
Ethnicity   
White 44 (72) 
Black 2 (3) 
Asian 11 (18) 
Hispanic/Latino 1 (2) 
Mixed race 1 (2) 
Other 2(3)  
  
Parents & Young people 19 (100) 
Place of residence in UK  
North East  0 (0) 
North West  0 (0) 
Yorkshire and The Humber 1 (5) 
East Midlands 1 (5) 
West Midlands 0 (0) 
East of England 0 (0) 
London 4 (21) 
South East 2 (11) 
South West 3 (16) 
Scotland 0 (0) 
Wales 0 (0) 
Ireland 4 (21) 
Outside UK 
 
4 (21) 
Ethnicity   
White 16 (84) 
Black 2 (11) 
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Characteristic N (%) 
Asian 0 (0) 
Hispanic/Latino 0 (0) 
Mixed race 0 (0) 
Other 
 
1 (5) 
Average child age 10.5, (s.d. 1.9) 
 
   
SUPPLEMENTARY 4 –  
Table S4.1 – Outcomes suggested after R1 of the Delphi survey 
 
Additional outcome 
suggested 
Stakeholder & 
Score  
Score Notes  
 
Frequency of hospital 
out-patient 
attendance for BECTS 
review 
 
Professional 
 
 
 
 
 
7 New outcome identified 
 
Outcome: 
Attendance for 
medical 
appointments in 
outpatients 
Domain: Seizures 
Description: 
Routine 
attendances for 
medical epilepsy 
management 
 
 
seen by consultant 
with specialist 
expertise in epilepsy 
 
Professional 7 No new outcomes 
represented in 
free-text response/already 
covered in outcomes.  
seen by consultant 
paediatric neurologist  
 
Professional 7 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
seen by paediatric 
epilepsy specialist 
nurse 
 
Professional 7 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
taking anti-
convulsant for BECTS 
 
Professional 8 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Hospital attendances 
 
Professional 4 New outcome identified 
 
Outcome: 
Unplanned hospital 
attendances at 
Accident & 
Emergency 
Domain: Adverse 
events 
Description:  
Visiting the hospital 
   
Additional outcome 
suggested 
Stakeholder & 
Score  
Score Notes  
 
due to an acute 
medical emergency 
 
 
Hospital admissions 
 
Professional 4 New outcome identified 
Outcome: 
Unplanned  
epilepsy-related 
admission to 
hospital as inpatient  
Domain: Adverse 
Events 
Description: 
Unexpectedly 
needing to be 
admitted to hospital  
 
Change in 
medication; e.g. 
withdrawal or 
addition of AED 
 
Professional 5 New outcome identified 
Outcome: Drug 
treatment failure 
(adverse events or 
poor seizure 
control)  
Domain: Adverse 
Events 
Description: 
stopping medication 
because it’s not 
working or causing 
problems 
 
Epilepsy in this 
person drug resistant 
(by ILAE criteria) 
 
Professional 4 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
list comorbidities 
 
Professional 7 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Evidence of 
parasomnia with 
awakening at night 
 
Professional 
 
7 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Percentage of 
diagnosed 
Professional 9 No new outcomes 
represented in 
   
Additional outcome 
suggested 
Stakeholder & 
Score  
Score Notes  
 
comorbidities in 
children with RE 
 
free-text response/already 
covered in outcomes. 
The types of seizures 
seen in the child with 
the diagnosis 
 
Professional 6 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
The percentage of 
children with RE 
whose epilepsy 
evolves or becomes 
uncontrollable.  
 
Professional 9 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
speech regression / 
aphasia 
 
Professional 9 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Awareness of SUDEP Parent 8 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
TICS Parent 8 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Improvement of 
deterioration of 
school work after 
starting treatment 
 
Professional 6 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
Ability to play Sport Parent 4 No new outcomes 
represented in 
free-text response/already 
covered in outcomes. 
 
   
Supplementary 5 – Consensus meeting minutes and participants 
 
Table S5.1 – Participants present at the consensus meeting 
 
Initials Meeting role Stakeholder Group Membership 
CM Meeting facilitator/chair n/a Research team 
HC Assistant Facilitator n/a Research team 
SI Assistant n/a King’s College 
London 
SL Family Engagement Officer n/a Research team 
DKP Participant Professional 
(Paediatric 
neurologist) 
Delphi survey 
participant/ 
Research team 
PG Participant Professional 
(consultant in sleep 
medicine) 
Delphi survey 
participant/ 
Research team 
BC Participant Professor of 
children’s nursing 
Research 
team/voted in 
meeting 
JH Participant Professional 
(Paediatrician) 
Delphi survey 
participant 
DJ Participant Professional 
(Consultant in sleep 
medicine) 
Delphi survey 
participant 
CT Participant Professional 
(Clinical 
Psychologist) 
Delphi survey 
participant (R1) 
SM Participant Professional 
(Physiologist) 
Delphi survey 
participant 
RW Participant Professional 
(Paediatric 
neurologist) 
Delphi survey 
participant 
DG Participant Professional 
(Paediatrician) 
Delphi survey 
participant 
MS Participant Parent of AS Delphi survey 
participant 
AS Participant Young Person Delphi survey 
participant 
CT Participant Parent of BT Delphi survey 
participant 
BT Participant Young Person Parent was a Delphi 
survey participant 
DR Participant Parent Research team 
JC Participant Parent Research team 
 
 
 
   
S5.2 Minutes of consensus meeting 
 
CHOICE – Core Health Outcomes in Childhood Epilepsy Consensus Meeting 
 
Facilitators: 
1. Christopher Morris 
2. Holly Crudgington 
 
Assistants: 
1. SL (Family Engagement Officer) 
2. SI (Assistant) 
 
Eligible to vote: 
Professionals (n=9) 
1. RW (Paediatric neurologist) 
2. DJ (Consultant in Sleep medicine) 
3. BC (Professor of Children’s Nursing) 
4. CT (Clinical Psychologist) 
5. PG (Consultant in Sleep medicine) 
6. DP (Paediatric neurologist) 
7. JH (Paediatrician) 
8. DG (Paediatrician) 
9. SM (Physiologist) 
 
Parents (n=4) 
1. JC 
2. DR 
3. CT 
4. MS 
 
 
Young People (n=2) 
1. AS 
2. BT 
 
Total present at meeting: 19 
Total voting: 15 
 
 
 
 
 
 
 
 
 
 
   
Outcomes in from the Delphi, prior to meeting (n=11) 
 
Outcome 1. Seizure Freedom 
Outcome 2. Seizure Frequency 
Outcome 3. Seizure duration 
Outcome 4. Memory 
Outcome 5. Self-harm 
Outcome 6. Fears of having a seizure 
Outcome 7. Learning 
Outcome 8. Concentration 
Outcome 9. Overall Quality of Life 
Outcome 10. Adverse events or reactions 
Outcome 11. Drug treatment failure events (adverse events or poor seizure control) 
 
Outcomes voted in after the meeting (n= 28) 
 
Outcome 12. Seizure Severity 
Outcome 5. Total time spent asleep at night  
Outcome 6. Total time spent asleep in 24 hours 
Outcome 7. Awakenings from sleep 
Outcome 8. Breathing difficulties 
Outcome 9. Daytime Sleepiness 
Outcome 13. Movement ability – Gross motor function 
Outcome 14. Manual ability (fine motor function) 
Outcome 16. Ability to join activities with others 
Outcome 18. Friendships 
Outcome 19. Engagement in school life 
Outcome 16. Ability to join activities with others  
Outcome 17. Experience of other people’s attitudes towards epilepsy 
Outcome 22. Behavioural concerns  
Outcome 23. Impulsivity 
Outcome 25. Feelings about having epilepsy 
Outcome 31. Self-esteem 
Outcome 32. Mood swings 
Outcome 34. Concealment 
Outcome 36. Literacy 
Outcome 37. Speech & Language 
Outcome 41. School attendance 
Outcome 42. Academic attainment 
Outcome 43. Executive functioning 
Outcome 46. Relationships with parents & siblings 
Outcome 47. Family life 
Outcome 48. Parental health  
Outcome 51. Epilepsy specific attendance at A&E and/or unplanned admission to the ward 
  
Total: 39 
 
   
 
Voting Results: 
 
Outcome 4 – Seizure Severity 
Definition: How bad seizures are in terms of effects on the person during and after seizures – 
such as falls or injuries, incontinence, confusion and time to recover afterwards 
 
Comments: 
- AS (young person): ‘Very important’ 
 
Votes in 
Professionals: 9/9 
Parents: 4/4 
Young People: 2/2 
Total: 15/15 
 
Result: CONSENSUS IN 
 
 
Outcome 5 – Time to fall asleep 
Definition: Time it takes to fall asleep from snuggling down 
 
Votes in 
Professionals: 0/9 
Parents: 0/9 
Young people: 0/9 
Total: 0/15 
 
Result: CONSENSUS OUT 
 
 
Outcome 6 – Time spent asleep in 24 hours 
Definition: Total time spent asleep each day 
 
Comments: 
- AS (Young Person) – Time spent asleep not that important – not critical to research 
- JH (Professional) – Sleep deprivation is a strong driver for seizures and probably 
severity 
- RW (Professional) – Day and night should be split 
- CM (Facilitator) – Can re define if we want to. Could change to ‘total time spent 
asleep at night’ 
 
Vote on ‘Time spent asleep each day’ 
Votes in 
Professionals: 7/8 (BC didn’t answer) 
Parents: 4/4 
Young People: 0/2 
   
Total: 11/14 
 
Result: CONSENSUS OUT 
 
Vote on ‘Time spent asleep in 24 hours’: CONSENSUS IN 
Vote on ‘Time spent asleep at night’: CONSENSUS IN 
 
Outcome: Time spent asleep at night  
Definition: Total time spent asleep at night 
 
Votes in 
Professionals: 8/8  
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 7 – Awakenings from sleep 
Definition: Waking in the night that parents/carers are aware of 
 
Comments: 
- JC (Parents): Critical 
 
Votes in 
Professionals: 9/9 
Parents: 4/4 
Young People: 2/2 
Total: 15/15 
 
Results: CONSENSUS IN 
 
 
Outcome 8 – Breathing difficulties during sleep 
Definition: Might include snoring or gasping for breath 
 
Comments: PG (Professional) Important, epilepsy or not 
 
First vote 
Votes in 
Professionals:7/9 
Parents: 4/4 
Young People: 0/2 
Total: 11/15 
 
   
Second vote 
Votes in 
Professionals: 9/9 
Parents: 4/4 
Young People: 2/2 
Total: 14/15 
 
Result: CONSENSUS IN 
 
 
Outcome 9 – Daytime sleepiness 
Definition: Feeling sleepy or actually sleeping during the day 
 
Votes in: 
Professionals: 9/9 
Parents: 3/4 
YP: 2/2 
Total: 14/15 
 
Results: CONSENSUS IN 
 
 
Outcome 10 – Fatigue 
Definition: Lacking in energy 
 
Votes in: 
Professionals: 0/9 
Parents: 0/4 
Young People: 0/2 
Total: 0/15 
 
Result: CONSENSUS OUT 
 
 
 
 
Outcome 11 – Pain 
Definition: Unpleasant, physical sensation 
 
Comments:  
- JC (Parent) – felt pain fitted in with severity of seizure 
 
Professionals: 0/9 
Parents: 0/4 
Young People: 0/2 
Total: 0/15 
 
   
Result: CONSENSUS OUT 
 
 
Outcome 13 – Movement ability – Gross motor function 
*Combined Coordination & Balance outcome and definition. 
Definition: Using parts of the body together efficiently, such as to ride a bike, or stand on one 
leg, catching and throwing. Running, jumping, hopping, throwing. 
 
Comments:  
- AS (Young person) felt it was very important for school especially for moving around 
to different lessons. 
 
Professionals: 9/9 
Parents: 4/4 
Youn People: 2/2 
Total: 15/15 
 
Result: CONSENSUS IN 
 
 
 
 
Outcome 14 -Manual ability (fine motor function) 
Definition: Dexterity (skill) in handling objects, handwriting 
 
Comments:   
- DR (Parent) thinks movement ability, coordination & balance, and manual ability are 
all the same. 
- CT (Professional) Wondered if it was ‘critical’ to measure 
- CT (Parent) In order to get support for a child, anything that can support an 
application for parents. 
 
Vote in 
Professionals: 8/9 
Parents: 4/4 
Young People: 2/2 
Total: 14/15 
 
Result: CONSENSUS IN 
 
 
 
Outcome 15: Self care 
Definition: Daily routines such as eating, washing, dressing and toileting. 
 
Note: RW left the meeting. Total out of 14 professionals. 
 
   
Professionals 
Parents 
Young People 
Total 
 
Results: CONSENSUS OUT  
 
 
Outcome 16: Ability to join activities with others 
Definition: Joining in with people such as playing out with friends, sleepovers, doing sports, 
joining in things 
*Combined Social life with this outcome, added in the word ‘sleepovers’. 
 
Vote in (when combined) 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 
 
Result: CONSENSUS IN 
 
 
 
Outcome 17: Ability to play on one’s own 
Definition: Reading, computer games, imaginary play etc.  
 
Professionals: 0/8 
Parents: 0/4 
Young People: 0/2 
Total: 0/14 
 
Result: CONSENSUS OUT 
 
Outcome 18: Friendships 
Definition: Forming and maintaining friendships 
 
Vote in: 
Professionals: 7/8 
Parents: 4/4 
Young People: 2/2 
Total: 13/14 
 
Result: CONSENSUS IN 
 
Outcome 19: Engagement in school life 
Definition: Feeling part of the school community 
 
   
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 21: Experience of other people’s attitudes towards epilepsy  
Definition: How people behave towards someone with epilepsy which could include things 
like bullying or social exclusion 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
Outcome 22: Behavioural Concerns 
*Name changed from Behaving appropriately 
Definition:  Being able to control emptions and respond to situations in context 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
Outcome 23: Impulsivity 
Definition: Acting without thinking 
 
Vote in 
Professionals: 7/8 
Parents: 3/4 
Young People: 1/2 
Total: 11/14 
 
Result: CONSENSUS IN 
 
Outcome 24: Fidgeting 
   
Definition:  
 
Vote in 
Professionals: 0/8 
Parents: 0/4 
Young People: 0/2 
Total: 0/14 
 
Result: CONSENSUS OUT 
 
 
Outcome 25: Feelings about having epilepsy  
Definition: Feeling like other people of the same age 
*combination of Feeling normal, Feelings about having epilepsy, Happiness, Sadness, 
Worried, Annoyed. 
Definition: 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
Outcome 31: Self esteem 
Definition: Overall feelings about yourself 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
Outcome 32: Mood swings 
Definition: Quick unexplained changes of mood 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
   
Outcome 34: Concealment 
Definition: Quick unexplained changes of mood 
 
Vote in 
Professionals: 6/8 
Parents: 4/4 
Young People: 2/2 
Total: 12/14 
 
Result: CONSENSUS IN 
 
 
Outcome 36: Literacy 
Definition: Reading, writing, spelling 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
Outcome 37: Speech & language 
Definition: Making yourself understood and understanding when spoken to 
 
Vote in 
Professionals: 7/8 
Parents: 4/4 
Young People: 2/2 
Total: 13/14 
 
Result: CONSENSUS IN 
 
 
Outcome 41: School attendance 
Definition: Turning up and engaging in school curriculum 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
   
 
 
Outcome 42: Academic attainment 
Definition: Reaching potential through studying and completing assigned tasks and projects 
and advancing to next stage of education 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 43: Executive functioning 
Definition: The ability to plan and organise complex activities and set goals and manage 
your time. Executive functions help you manage life tasks such as organizing a trip, 
homework and school projects.  
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 46: Relationships with parents & siblings 
Definition: Getting along well with and feeling close to other members of the family  
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 47: Family life 
Definition: Impact of epilepsy on family life such as parent work opportunities or/leisure time 
 
   
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
 
Outcome 48: Parental health 
Definition: Parents physical and emotional health 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
 
 
Outcome 50: Epilepsy specific attendance at A&E and/or unplanned admission to the 
ward 
Definition: unexpectedly need to be admitted to hospital 
 
Vote in 
Professionals: 8/8 
Parents: 4/4 
Young People: 2/2 
Total: 14/14 
 
Result: CONSENSUS IN 
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Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3, 5-7 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
6-7 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
Protocol 
published (7, 8) 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
9 
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9, 10, 
Supplementary 1  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
Supplementary 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
9, 10 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
9-10, 13 
   
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
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this piece of 
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9-10, 13-14 
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Not relevant to 
this piece of work 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
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Not relevant to 
this piece of work 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
9-10, 13-14, 
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Supplementary 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
Supplementary 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Not relevant to 
this piece of work 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Not relevant to 
this piece of work 
   
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Not relevant to 
this piece of work)  
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Not relevant to 
this piece of work 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
Not relevant to 
this piece of work 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
15-21 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
15-21 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
15-21  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
21-22 
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Title 1a Identify in the title 
that the paper 
reports the 
development of a 
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1 
Abstract 1b Provide a structured 
summary 
3 
INTRODUCTION 
Background and 
objectives 
2a Describe the 
background and 
explain the rationale 
for developing the 
COS 
5-7 
 2b Describe the specific 
objectives with 
reference to 
developing a COS 
5-7 
Scope 3a Describe the health 
condition(s) and 
populations(s) 
covered by the COS 
5-7, 9 
 3b Describe the 
intervention(s) 
covered by the COS 
5-7, 9 
 3c Describe the 
setting(s) in which 
the COS is to be 
applied 
5-7, 9 
METHODS    
Protocol/Registry 
Entry  
4 Indicate where the 
COS development 
protocol can be 
accessed, if 
available, and/or the 
study registration 
details 
8 
Participants 5 Describe the 
rationale for 
stakeholder groups 
involved in the COS 
development 
5-8, 10-12, 14-15 
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criteria for 
participants from 
each group, and a 
description of how 
the individuals 
involved were 
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Information Sources 6a Describe the 
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used to identify an 
initial list of 
outcomes 
9-10, Figure 1, 
Supplementary 1 & 
2 
 6b  Describe how 
outcomes were 
dropped/combined, 
with reasons (if 
applicable) 
9, Supplementary 2 
& 4 
Consensus Process 7 Describe how the 
consensus process 
was undertaken 
10-12, 14-15 
Supplementary 5  
Outcome Scoring 8 Describe how the 
outcomes were 
scored and how 
scores were 
summarised 
10-12, 14-15 
 
Consensus 
Definition 
9a Describe the 
consensus definition 
10-12, 14-15 
 
 9b Describe the 
procedure for 
determining how 
outcomes were 
included or excluded 
from consideration 
during the 
consensus process 
10-12, 14-15 
Table 4, 
Supplementary 4 
and 5 
Ethics and Consent 10 Provide a statement 
regarding the ethics 
and consent issues 
for the study 
8 
RESULTS    
Protocol Deviations 11 Describe any 
changes from the 
protocol (if 
applicable), with 
reasons, and 
describe what 
10, 14-15 
 
   
impact these 
changes have on the 
results 
Participants 12 Present data on the 
number and 
relevant 
characteristics of 
the people involved 
at all stages of COS 
development 
14-15, 
Table 2 and 
Supplementary 2 & 
5 
Outcomes 13a List all outcomes 
considered at the 
start of the 
consensus process 
Figure 2 
 13b Describe any new 
outcomes 
introduced and any 
outcomes dropped, 
with reasons, during 
the consensus 
process 
Table 4, 
Supplementary 4 & 
5 
COS 14 List all the outcomes 
in the final COS  
Figure 2 
DISCUSSION    
Limitations 15 Discuss any 
limitations in the 
COS development 
process 
15-21 
Conclusions 16 Provide an 
interpretation of the 
final COS in the 
context of other 
evidence, and 
implications for 
future research. 
17-21 
OTHER 
INFORMATION 
   
Funding 17 Describe sources of 
funding/role of 
funders 
21 
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22 
   
 
